Chapter 63: Drugs Affecting Calcium Levels and Bone Mineralization

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine you are managing a bank,

right?

But in this specific bank, the checking count is just absolutely critical that if the balance drops even a fraction of a percent,

the tellers are literally instructed to demolish the building's structural foundation.

Just to keep the checking account funded.

Exactly.

Just to keep that checking account funded.

Sounds completely irrational.

But when it comes to the human body, that is exactly how our physiology operates.

Yeah, it really is.

So welcome to the deep dive.

We are bringing you this session on behalf of the Last Minute Lecture Team, Cutting Through the Noise for You, the advanced practice student.

We're going to give you exactly what you need to know from Chapter 63 of Lane's Pharmacotherapeutics.

Which is drugs affecting calcium levels and bone mineralization.

Right.

It's a massive topic.

We're going to follow the exact flow of the text, starting with the path of physiology so we understand the body's goals, then jumping into rational drug selection, and finally covering dosing, monitoring,

and safe patient -centered care.

And to really grasp how we use these drugs clinically, we have to start with why the body is so fiercely protective of that checking account you mentioned.

I mean, the calcium floating in our blood.

Okay, let's unpack this.

The text notes calcium serves critical functions across four major systems.

In the skeletal system, obviously, it provides structural integrity,

but outside the bone.

It's everywhere.

Right.

It regulates axonal tight ability in the nervous system, excitation contraction coupling in the muscular system, and it plays a massive role in cardiovascular system for myocardial contraction and coagulation.

So explain what that actually looks like in the body.

Yeah, think of calcium as the literal spark for communication and movement.

In the nervous system, calcium channels regulate how easily a nerve fires.

The action potential.

Exactly.

And in the muscular system, that excitation contraction coupling, that means calcium is the physical trigger causing muscle fibers to slide together.

Without it, you have zero muscle flexion.

Oh, wow.

And the heart.

Same thing.

That sparking mechanism causes the myocardium to beat.

It also signals blood vessels to constrict and acts as a necessary co -factor in the clotting cascade.

So if blood calcium drops, it's not just weak bones.

The nervous system gets twitchy.

The heart rhythm gets thrown off.

Muscles fail.

That really explains why the dietary requirements are so hyperspecific.

They have to be.

According to the National Academy of Medicine guidelines in table 63 .1, our daily requirements shift based on life stage.

Like we need 1300 milligrams a day as teenagers building peak bone mass.

Right.

Because of the rapid growth.

Yeah.

And then it drops to a thousand milligrams for adults and goes back up to 1200 milligrams for older women during and after menopause.

And here is the trap.

People just assume they need to take a pill to hit those targets.

The text highlights a staggering statistic.

What's that?

43 percent of people in the U .S.

and nearly 70 percent of older women actively take calcium supplements.

Wow.

70 percent.

Yeah.

But surveys show most people actually get enough calcium from their diet alone.

I mean, dairy, tofu, broccoli, fortified juices.

The main exceptions are adolescent girls and postmenopausal women.

So if bone is our body's calcium savings account and blood is the checking account, blindly depositing too much into checking by oversupplementing,

that has to cause a backup.

Oh, absolutely.

If you're already getting a thousand milligrams from your diet and you throw a massive supplement on top, where does all that excess go?

It doesn't just pass harmlessly through the system.

Taking excess supplemental calcium significantly increases the risk for vascular calcification.

It deposits in the arteries.

Literally in the blood vessels, yes.

This elevates the risk for myocardial infarction, stroke, and nephrolithiasis.

Kidney stones.

Right.

Patients should only use supplements to make up the specific deficit between their diet and their daily requirement.

Not a milligram more.

Got it.

Now, to keep this checking account perfectly balanced, the body relies on three hormonal regulators.

Parathyroid hormone or PTH,

vitamin D, and calcitonin.

The big three.

Yeah.

PTH and vitamin D are the promoters.

They pull calcium from the bone, they increase absorption in the gut, and they decrease excretion in the kidneys,

while calcitonin is the opposing force pushing blood calcium levels down.

Which brings us to the golden rule of this entire system.

Preserving calcium levels in the blood always takes priority over preserving calcium in the bone.

The demolition of the bank building.

Exactly.

The body will ruthlessly strip calcium from the skeleton via PTH just to keep the heart beating and the nerves firing, even if it leaves the structural foundation weak and porous.

So understanding that relentless priority perfectly sets up the clinical realities of what happens when the regulatory system fails.

The text outlines two dangerous extremes.

Let's look at hypercalcemia first.

Sure.

So mild hypercalcemia is often asymptomatic at first, but as the concentration rises, it impairs kidney function.

Causing polyuria, right?

Excessive urination.

Yes.

And those kidney stones we mentioned.

You also see neurologic sluggishness, severe cardiac dysrhythmias, and soft tissue calcification.

And what's usually the root cause of these life -threatening elevations?

Most frequently, it's caused by cancers that either metastasize to the bone or secrete PTH -like substances or just primary hyperparathyroidism.

On the flip side, we have hypocalcemia.

If calcium is the spark that keeps nerves stable, I imagine a lack of calcium makes the nervous system hyper excitable.

You see tetany, severe painful muscle spasms and convulsions.

We also see systemic bone disorders like pageant disease mapped out here.

Where increased bone resorption is replaced by abnormal, painful,

structurally weak bone.

Right.

It's highly vascular, but very weak.

Because hypocalcemia is so directly linked to a failure of our regulatory system, our first -line pharmacotherapeutic defenses are simple.

We replace what's missing.

Right.

Calcium salts and vitamin D.

Let's start with mild hypocalcemia.

When we treat it with oral calcium preparations, the clinical reasoning requires, well, careful attention to this specific formulation.

Yeah.

Not all calcium is created equal.

Different salts yield different amounts of usable elemental calcium.

The text mentions calcium carbonate has the highest yield at 40%, right?

It does, but there's a catch.

It requires stomach acid to dissolve properly.

So if you have a patient taking a proton pump inhibitor, a PPI, they aren't going to absorb it well.

Because the acid is blocked.

Exactly.

For a patient on a PPI, the provider should select calcium citrate.

It has a lower percentage of elemental calcium, but it is highly soluble and doesn't rely on an acidic environment.

Yes.

Great clinical pearl.

But if a patient is in the ER with severe hypocalcemic tetany, an oral tablet isn't going to cut it.

We need intravenous calcium.

Immediately.

So the text contrasts calcium chloride with calcium gluconate.

Why is 5e calcium gluconate universally preferred?

Well, intravenous calcium chloride is incredibly hypertonic.

It is highly irritating to the veins.

It burns.

It burns.

And worse, if extravasation occurs, meaning the IV slips and that highly concentrated chloride leaks into the surrounding tissue, it causes severe necrosis.

Oh, tissue sloughing.

Massive tissue sloughing.

Calcium gluconate carries significantly less risk for tissue damage while still, rapidly restoring blood calcium levels.

Okay.

So if you are discharging a patient on oral calcium,

the education you provide is literally the barrier between them and a return trip to the ER.

Calcium binds to certain medications in the gut, rendering both useless.

Yeah.

You have to separate calcium administration from tetracyclines, quinolone antibiotics, and thyroid hormones.

What about food interactions?

Patients need to avoid taking calcium with foods containing oxalates like spinach or phytic acid like bran.

Those compounds bind the calcium and just block absorption entirely.

Good to know.

So then we have to consider how that calcium actually gets utilized, which is dictated by vitamin D.

The text draws a sharp distinction between ergocalciferol, known as D2, and cholecalciferol, or D3.

Right.

D2 is plant -based, often found in fortified foods.

D3 is naturally produced in human skin upon exposure to sunlight.

And clinically, D3 is preserved, isn't it?

Yeah.

It's significantly more effective at raising and maintaining lead levels.

What's fascinating here is that calling it a vitamin is almost a misnomer.

Because it's a hormone.

It functions entirely as a hormone.

It requires a two -step metabolic activation.

First, the liver converts it into an intermediate form.

Then the kidneys convert it into its fully active state.

So when a provider wants to definitively diagnose a deficiency, what lab are they pulling?

They don't measure the active form.

They measure the intermediate serum 25 -hydroxyvitamin D levels.

The clinical target for bone health sits right between 30 and 60 nanograms per milliliter.

Okay.

So we have tools to pull blood calcium levels up.

But what if we need to force runaway calcium levels down?

This brings us to Cinecalcet and calcitonin.

Cinecalcet, under the brand name Sinsepar, is a calcimetic.

Its mechanism is, it effectively tricks the parathyroid gland.

It literally tricks it.

Yeah.

It binds to the calcium -sensing receptors on the gland and increases their sensitivity.

It makes the body perceive that there is way more calcium in the blood than there actually is.

Oh, which rapidly suppresses the release of parathyroid hormone.

Exactly.

We use it specifically for hyperparathyroidism, particularly in patients with chronic kidney disease.

But because it forces calcium levels down so efficiently, the primary adverse effect to monitor has to be

hypocalcemia.

Providers have to watch for the exact symptoms we discussed earlier,

cramping, myalgias, and tetany.

Right.

The other option for lowering calcium is calcitonin, specifically salmon -derived calcitonin like miocalcin.

It acts in direct opposition to PTH, right?

Yes.

It inhibits osteoclasts, the cells responsible for breaking down bone, while simultaneously increasing renal excretion of calcium.

I noticed it's salmon -derived.

Why use a fish hormone instead of human calcitonin?

Salmon calcitonin has a much longer half -life, and is significantly more potent than human calcitonin, making it a much better drug.

However, its clinical utility is heavily debated.

Why is that?

It's a proof for postmenopausal, osteoporosis, and Paget disease, right?

It is, but it's rarely a first -choice drug.

The intranasal spray formulation was actually pulled from the Canadian market back in 2013 due to a link with an increased risk of malignancy.

Wow.

But it's still available in the US.

It is.

The FDA issues a stern warning to clinicians to weigh the risks versus the benefits carefully because, honestly, there are safer, more effective drugs available.

Which naturally leads us to those more effective drugs.

If calcitonin isn't strong enough to halt bone breakdown in osteoporosis or Paget disease,

we reach for the true workhorses, the bisphosphonates.

The prototype we study here is alendronate.

Let's break down how alendronate works.

Yeah, earlier I was conceptualizing it like a reinforced steel beam that gets installed into the bone, but that doesn't really capture the actual mechanism, does it?

Not quite.

These drugs are structural analogs of pyrophosphate.

That means they look like a normal constituent of the bone.

When they are administered, they incorporate themselves directly into the bone matrix.

So they just sit there.

Think of them more like a poison pill hidden inside the bone.

Okay.

When an osteoclast attaches to the bone surface and attempts to ingest the matrix to break it down, it accidentally consumes the alendronate.

Once inside the osteoclast, the drug inhibits its biochemical activity.

Rendering it useless.

Right.

And it decreases the overall number of osteoclasts.

Because it becomes physically embedded in the bone, it remains active there for decades.

Here's where it gets really interesting.

If it works so locally within the bone, why is the administration process so notoriously strict?

I mean, the patient education for dysphosphonates is intense.

It comes down to extremely poor pharmacokinetics.

The bioavailability of oral alendronate is practically non -existent.

Like how low?

Less than 1%.

Even under ideal conditions.

And if it is taken with any food or even orange juice, absorption drops to absolute zero.

The molecules are simply too bulky to cross the gastrointestinal membrane easily.

So patients must take it in the morning on a completely empty stomach with a full glass of water.

Yes.

And then there is a mechanical safety alert.

They must remain fully upright, either sitting or standing, for a minimum of 30 minutes after swallowing the pill.

And if they don't?

If they lie back down in bed?

If the pill gets stuck or refluxes back into the esophagus, prolonged contact with the mucosal lining causes severe esophagitis.

It can rapidly progress to esophageal ulceration.

Gravity just ensures it passes quickly into the stomach where it is safer.

We also have to unpack two rare but incredibly serious adverse effects associated with long -term bisphosphonate use.

The first is atypical femur fractures.

Which is crazy.

We are giving a drug specifically to prevent fractures, but it can actually cause them.

It seems like a total paradox, but it makes perfect sense when you understand bone physiology.

Bone is dynamic, right?

It constantly remodels itself to repair the microscopic cracks we accumulate just by walking around.

This phosphonates suppress bone turnover so profoundly that the osteoclasts can never clear away the damaged bone to make room for repair.

So the microcracks just stay there?

Over several years, those microcracks accumulate.

The bone density remains high on a scan, but the structural integrity becomes super brittle.

This leads to a massive fracture occurring with little to no trauma.

Just from stepping off a curb?

Exactly.

This is why clinical guidelines often recommend a drug holiday, re -evaluating and potentially pausing therapy after five years.

The second complication is osteonecrosis of the jaw, or ONJ, where the jawbone literally begins to die and become exposed.

Yeah, it's brutal.

Because of this risk, patients require a comprehensive dental exam before ever starting bisphosphonate therapy.

Right, because if they need an extraction.

Any invasive dental procedure must be completed and healed prior to initiating the drug.

Because that suppressed bone turnover means the jaw will simply not heal normally once the drug is in their system.

Makes sense.

So we've established that controlling osteoclasts is the primary goal of anti -resorptive therapy.

Naturally, the body has its own brake pedal for osteoclasts, estrogen.

Right.

Which explains why menopause drastically accelerates bone resorption.

When natural estrogen levels plummet, the osteoclasts lose that brake pedal and begin rapidly breaking down bone.

And estrogen replacement therapy absolutely restores that brake.

It is highly effective at preventing post -menopausal osteoporosis.

But the dilemma for the provider is that systemic estrogen therapy carries unacceptable risks for many patients.

What kind of risks?

Well, if given unopposed by progestin, it increases the risk for endometrial cancer.

It also elevates the risk for breast cancer, cholecystitis, gallbladder inflammation,

and serious thromboembolic events.

Like deep vein thrombosis and stroke.

Exactly.

Because estrogen heavily influences the clotting cascade.

So pharmacology provided a compromise to navigate those risks.

Selective estrogen receptor modulators, or CIRMS.

The prototype is Riloxafine, sold under the brand name Vista.

Riloxafine is ingenious.

It binds to estrogen receptors, but its physical structure causes it to act differently depending on the specific tissue it occupies.

So it acts as an agonist, mimicking the effects of estrogen in the bone, providing that necessary break on the osteoclasts and in lipid metabolism.

Right.

But it acts as an antagonist, blocking the effects of estrogen in the breast and the endometrium.

You gain the bone protection without promoting breast or uterine cancer.

But it doesn't eliminate the cardiovascular risks.

The text emphasizes a black box warning for Riloxafine that any prescriber must know.

It carries the exact same risk as systemic estrogen for DVT, pulmonary embolism, and fatal stroke.

And patient education here isn't just about taking the pill, you know.

It's about anticipating life events.

Patients must be instructed to discontinue Riloxafine at least 72 hours prior to any event that involves prolonged immobilization.

Like a scheduled surgery.

Or even an extended international flight.

They need to be off the drug and they cannot resume it until full ambulation is restored.

Okay, up to this point,

every single drug we've discussed, calcitonin, bisphosphonates, CIRMS, works by stopping bone breakdown.

They suppress the osteoclasts.

But what if the bone is already severely depleted?

Can we actively build new bone?

We can.

Using terapeurotide and apilopurotide.

These are recombinant human parathyroid hormones and analogs.

Hold on.

Earlier, we clearly established that parathyroid hormones' primary job is to ruthlessly strip calcium out of the bone to raise blood levels.

How does administering a PTH analog result in building new bone?

It's a remarkable pharmacodynamic paradox and it hinges entirely on the route and timing of administration.

If you administer a continuous IV infusion of PTH, the body responds exactly as you'd expect.

Osteoclasts activate and the bone breaks down.

However, terapeurotide is administered via daily subcutaneous injections.

So it's intermittent.

Yes.

These daily intermittent injections create a transient, short -lived spike in PTH levels.

For reasons we are still unraveling, that specific transient spike selectively stimulates the osteoblasts, the cells responsible for depositing new bone matrix while largely ignoring the osteoclasts.

Wow.

It forces the builders to work faster than the demolition crew.

Exactly.

But the clinical hurdles for these drugs are immense.

Terapeurotide requires strict refrigeration and both drugs are financially inaccessible for many.

I mean, we're talking between $2 ,000 and $3 ,500 a month.

And they also carry a strict black box warning.

In animal testing, these drugs caused a dose -dependent increase in osteosarcoma, a malignant bone cancer.

So they can't be on it forever.

Right.

Because of this risk, they are subject to a strict lifetime limit.

A patient can only receive these drugs for a maximum of two years over their entire lifespan.

Furthermore, the first few injections frequently cause sudden orthostatic hypotension.

Oh, so they might pass out.

Yeah.

So patients must be educated to administer the dose in a safe environment where they can immediately sit or lie down if dizziness occurs.

Okay.

So what happens when a patient reaches that two -year limit?

Or if they have severe bone loss from bone metastases or long -term glucocorticoid use, and they need a completely different mechanism of action?

For those severe cases, we utilize Dinosumab, known by trade names like Prolia or Xdiva.

Dinosumab is a first -in -class monoclonal antibody.

It functions as an NKRL inhibitor.

Walk us through that communication pathway.

What exactly is NKRL?

Under normal physiological conditions, osteoblasts produce a protein called Arang -NKL.

This protein travels over and binds to rank receptors located on the surface of osteoclasts.

And that binding action is the signal that activates the osteoclast to mature and begin breaking down bone.

Precisely.

Dinosumab binds directly to the Arang -KL protein in transit, essentially cutting the communication wire.

The Arang -NKL never reaches the receptor, osteoclasts never receive the signal to form, and bone resorption halts completely.

And it's administered as a subcutaneous injection just once every six months for osteoporosis, right?

Yes.

But cutting that communication wire is powerful, and it requires intensive monitoring.

Because it halts bone breakdown so effectively, it can exacerbate existing hypocalcemia.

A provider must verify and correct blood calcium levels before administering the injection.

Absolutely.

It also suppresses certain immune functions, increasing the risk for serious infections like endocarditis and cellulitis.

And it carries the same risk for osteonecrosis of the jaw as the bisphosphonates.

And the most crucial piece of patient education regarding dinosumab is that a patient absolutely must not stop the medication without consulting their provider.

This is critical.

Once the inhibitor is removed from the system, all of that pent -up Arang -KL floods the receptors.

There is a massive immediate rebound in bone turnover.

And the risk for suffering multiple vertebral fractures just spikes dramatically within months.

It does.

The text also addresses a clinical scenario where the bone breakdown isn't just causing fractures, but flooding the checking accounts so rapidly it causes a life -threatening emergency.

Hypercalcemia of malignancy.

In a hypercalcemic crisis, the treatment protocol is sequential and highly specific.

Step one is aggressive IV isotonic saline, right?

Yes, you have to dilute the calcium in the blood and restore the fluid volume the patient has lost through polyuria.

Step two is administering furosemide, a loop diuretic.

Why specifically a loop diuretic?

You use a loop, not a thiazide, to aggressively force the kidneys to excrete the excess calcium.

Step three involves 5e glucocorticoids, which decrease the intestinal absorption of calcium.

And step four utilizes IV bisphosphonates, like zoladronic acid, to shut down the osteoclasts, releasing calcium from the bone.

Okay, the text also mentions edetate disodium as an option for dire cases.

How does that fit into the protocol?

It is an absolute last resort.

Edetate disodium is a potent chelating agent.

It acts like a chemical claw circulating in the blood and rapidly binding up free calcium ions.

So it works fast.

Almost instantly.

But it is incredibly dangerous.

It can cause profound hypocalcemia, leading to fatal dysrhythmias, and the chelated complexes can cause severe nephrotoxicity.

So you only use it when the hypocalcemia is immediately life -threatening and other therapies have failed?

Correct.

Alright, we have dissected the entire pharmacological toolbox.

But for the advanced practice nurse or physician assistant looking at a patient chart, how do you decide when it is time to prescribe these medications?

I mean, we don't just guess.

We rely on diagnostic reasoning.

The gold standard diagnostic tool is the DXA scan, which measures bone mineral density.

The results are reported as a T -score comparing the patient's density to a healthy young adult.

And a normal T -score is minus 1 .0 or higher.

Right.

Osteopenia, indicating low bone mass, falls between manageable 1 .0 and managed 2 .5.

And osteoporosis is definitively diagnosed with a T -score of managed 2 .5 or lower.

The T -score is just a snapshot.

To understand the actual clinical danger, the World Health Organization developed the FRAX tool.

It calculates a patient's specific 10 -year probability of suffering a major osteoporotic fracture.

Yeah, by factoring in age, weight, smoking status, glucocorticoid use, rheumatoid arthritis, and parental history of hip fracture.

Bringing the DXA scan and the FRAX tool together, we follow the treatment algorithm from the American Association of Clinical Endocrinologists, the AACE guidelines.

The AAC guidelines state you should initiate pharmacological treatment in postmenopausal cisgender women and cisgender men over 50 if they meet any one of three specific criteria.

Let's list those first.

First, a clinical history of a hip or vertebral fracture, regardless of their scan.

Second, a T -score of negatic 2 .5 or lower at the femoral neck or spine.

And third.

Third, a T -score in the osteopenia range, but combined with a high probability of fracture based on their individualized FRAX calculation.

The text also emphasizes that gender -specific, person -centered care is paramount here.

Cisgender men naturally develop a larger peak bone mass, so when they experience osteoporosis, it typically occurs later in life.

And it's frequently secondary to an underlying issue like low testosterone or prolonged systemic steroid use.

Right, and for transgender patients, the text highlights that while long -term, large -scale data is still lacking, clinical judgment is

Because a patient's bone density is heavily reliant on sex hormones.

Therefore, transgender patients who have undergone gonadectomy without subsequent, consistent hormone replacement therapy are placed at a particularly high risk for severe, accelerated bone loss.

We've covered incredible ground today.

We started with the physiological mandate that the body will relentlessly sacrifice the bone to keep the blood calcium checking account funded.

We did!

We explored the hormonal regulators, the anti -resorptive blockers from the strict administration of bisphosphonates to the tissue -specific serums.

And the paradoxical bone building of terapeurotide and the Ankello inhibition of dinosumab.

But reflecting on the entire scope of this chapter, there is a profound clinical tension we really have to acknowledge.

What's that?

We know that preserving blood calcium takes absolute physiological priority.

But consider the environment we live in today.

Our modern diets are heavily fortified, and 43 % the population is actively adding daily calcium supplements on top of that.

So we are constantly pushing deposits into a checking account that the body already prioritizes above all else.

Exactly.

We have to question if our aggressive focus on preserving the skeleton through widespread,

often unnecessary supplementation, is silently pushing our cardiovascular systems into uncharted territory.

Are we treating the bone at the direct expense of calcifying our arteries?

That's the real question.

It forces you to look at the whole patient, not just the single system you were trying to fix.

If you blindly deposit too much into checking,

eventually the system is going to back up.

A massive thank you to the Last Minute Lecture team for bringing this breakdown to life.

To all the advanced practice students preparing for exams or clinical rotations,

remember the mechanisms, respect the black box warnings, and always treat the patient, not just the lab value.

We will catch you on the next deep dive.